GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-02-22| ChinaM&A

Kinnate Buys Back $24 Million Worth Of Shares From China Venture Kinnjiu

by Joy Lin
Share To

Kinnate Biopharma, a San Francisco-based clinical-stage precision oncology company, has announced the acquisition of ownership stake in its China joint venture Kinnjiu Biopharma Inc. 

The transaction covers $24 million worth of preferred shares from funds managed by Series A investors OrbiMed and Foresite Capital Management. To make the acquisition possible, Kinnate drew funds from its cash reserves and shares of its common stock. 

Nima Farzan, CEO of Kinnate, commented, “We believe retaining the Kinnjiu structure will enable Kinnate to continue to invest in innovation and clinical development of its kinase inhibitors in the People’s Republic of China, Hong Kong, Macau and Taiwan.”

According to Kinnate, the transaction will not affect Kinnate’s cash runway, while its current assets are expected to last into mid-2024. As of September 30, 2022, Kinnate holds a total of $262.1 million in cash and cash equivalents, excluding cash from Kinnjiu. 

Related Article: CVS Adds Oak Street Health In $10.6 Billion Buy To Boost Primary Care Offerings

Initiating Phase 1 for Kinase Inhibitor Exafarenib

Formed in 2021, the joint venture Kinnjiu focuses on developing and commercializing Kinnate’s lead kinase inhibitors in mainland China, Hong Kong, Macau, and Taiwan regions. 

One of these kinase inhibitors is the pan-RAF inhibitor, exafarenib (KIN-2787 or KN-8701). Kinnate has announced the start of a Phase 1 clinical trial (for the regions mentioned above) for exafarenib in patients with advanced solid tumors harboring BRAF Class I, II, and III alterations, and/or have the NRAS mutation melanoma. 

The trial will enroll patients at more than 30 sites across the globe, and will evaluate exafarenib in two parts — dose escalation and dose expansion. In dose escalation Part A1, exafarenib will be administered as a monotherapy, while the drug will be combined with binimetinib, a MEK inhibitor, in Part A2. In Part B (dose expansion), exafarenib will be evaluated at a selected dose in cancers driven by BRAF Class II or Class III alterations. 

Exafarenib was granted Fast Track designation by the US FDA for stage IIb-IV melanoma in September 2022, adding to its status as an orphan drug. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Strengthening Genetic Screening Platform in APAC for Lung Cancer Precision Medicine: An Interview with Dr. Koichi Goto
2023-06-05
Pyramid Biosciences Bets $1B on Oncology Drug
2023-04-17
Pfizer-backed Flare Taps Caris To Boost Precision Oncology Pipeline
2023-04-17
LATEST
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
Lilly’s Omvoh’s Two-Year Journey Confirms Lasting Impact on Crohn’s Disease Treatment
2025-02-08
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
First-of-its-Kind Diagnostic Aid Uses a Single Hair Strand to Detect Autism Risk in Babies
2025-02-06
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top